Difference between revisions of "Blastic plasmacytoid dendritic cell neoplasm"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m (Text replacement - "'''dosing details in manuscript have been reviewed'''" to "'''dosing details in manuscript have been reviewed by our editors'''")
 
(16 intermediate revisions by 2 users not shown)
Line 3: Line 3:
 
[[#top|Back to Top]]
 
[[#top|Back to Top]]
 
</div>
 
</div>
−
{{#lst:Section editor transclusions|leuk}}
+
{{#lst:Editorial board transclusions|leuk}}
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
|-
 
|-
−
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
+
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
−
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
+
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
 
|}
 
|}
 
{{TOC limit|limit=3}}
 
{{TOC limit|limit=3}}
 +
=Guidelines=
 +
==NCCN==
 +
*''NCCN does not currently have guidelines at this granular level; please see [https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1411 NCCN Guidelines - Acute Myeloid Leukemia].''
 +
*'''2023:''' Pollyea et al. [https://doi.org/10.6004/jnccn.2023.0025 Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology] [https://pubmed.ncbi.nlm.nih.gov/37156478/ PubMed]
 +
 
=All lines of therapy=
 
=All lines of therapy=
 
==Tagraxofusp monotherapy {{#subobject:2471cc|Regimen=1}}==
 
==Tagraxofusp monotherapy {{#subobject:2471cc|Regimen=1}}==
Line 16: Line 21:
 
{| class="wikitable" style="width: 60%; text-align:center;"  
 
{| class="wikitable" style="width: 60%; text-align:center;"  
 
!style="width: 33%"|Study
 
!style="width: 33%"|Study
−
!style="width: 33%"|Years of enrollment
+
!style="width: 33%"|Dates of enrollment
 
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-
 
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260361/ Frankel et al. 2014 (STU 012013-061)]
 
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260361/ Frankel et al. 2014 (STU 012013-061)]
−
|2013-NR
+
|2013 to not reported
−
| style="background-color:#ffffbe" |Phase 1/2, <20 pts
+
| style="background-color:#ffffbe" |Phase 1/2, fewer than 20 pts
 
|-
 
|-
 
|[https://doi.org/10.1056/NEJMoa1815105 Pemmaraju et al. 2019 (STML-401-0114)]
 
|[https://doi.org/10.1056/NEJMoa1815105 Pemmaraju et al. 2019 (STML-401-0114)]
Line 34: Line 39:
 
</div></div>
 
</div></div>
 
===References===
 
===References===
−
# '''STU 012013-061:''' Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA, Konopleva M, Garnache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Rowinsky E. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014 Jul 17;124(3):385-92. Epub 2014 May 23. [http://www.bloodjournal.org/content/124/3/385.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260361/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/24859366 PubMed] NCT00397579
+
# '''STU 012013-061:''' Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA, Konopleva M, Garnache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Rowinsky E. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014 Jul 17;124(3):385-92. Epub 2014 May 23. [https://doi.org/10.1182/blood-2014-04-566737 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260361/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/24859366/ PubMed] [https://clinicaltrials.gov/study/NCT00397579 NCT00397579]
−
# '''STML-401-0114:''' Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019 Apr 25;380(17):1628-1637. [https://doi.org/10.1056/NEJMoa1815105 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/31018069 PubMed] NCT02113982
+
# '''STML-401-0114:''' Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019 Apr 25;380(17):1628-1637. [https://doi.org/10.1056/NEJMoa1815105 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/31018069/ PubMed] [https://clinicaltrials.gov/study/NCT02113982 NCT02113982]
−
##'''Update:''' Pemmaraju N, Sweet KL, Stein AS, Wang ES, Rizzieri DA, Vasu S, Rosenblat TL, Brooks CL, Habboubi N, Mughal TI, Kantarjian H, Konopleva M, Lane AA. Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. J Clin Oncol. 2022 Sep 10;40(26):3032-3036. Epub 2022 Jul 12. [https://doi.org/10.1200/jco.22.00034 link to original article] [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc9462530/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35820082/ PubMed]
+
##'''Update:''' Pemmaraju N, Sweet KL, Stein AS, Wang ES, Rizzieri DA, Vasu S, Rosenblat TL, Brooks CL, Habboubi N, Mughal TI, Kantarjian H, Konopleva M, Lane AA. Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. J Clin Oncol. 2022 Sep 10;40(26):3032-3036. Epub 2022 Jul 12. [https://doi.org/10.1200/jco.22.00034 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9462530/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35820082/ PubMed]
 
[[Category:Blastic plasmacytoid dendritic cell neoplasm regimens]]
 
[[Category:Blastic plasmacytoid dendritic cell neoplasm regimens]]
 
[[Category:Disease-specific pages]]
 
[[Category:Disease-specific pages]]
−
[[Category:Acute leukemias]]
+
[[Category:Myeloid neoplasms]]

Latest revision as of 12:25, 15 July 2024

Back to Top

Section editor
AK.JPG
 Ashwin Kishtagari, MD
Vanderbilt University
Nashville, TN, USA
LinkedIn
1 regimens on this page
1 variants on this page


Guidelines

NCCN

All lines of therapy

Tagraxofusp monotherapy

Regimen

Study Dates of enrollment Evidence
Frankel et al. 2014 (STU 012013-061) 2013 to not reported Phase 1/2, fewer than 20 pts
Pemmaraju et al. 2019 (STML-401-0114) 2014-2017 Phase 1/2 (RT)

Targeted therapy

21-day cycles

References

  1. STU 012013-061: Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA, Konopleva M, Garnache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Rowinsky E. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014 Jul 17;124(3):385-92. Epub 2014 May 23. link to original article link to PMC article PubMed NCT00397579
  2. STML-401-0114: Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019 Apr 25;380(17):1628-1637. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT02113982
    1. Update: Pemmaraju N, Sweet KL, Stein AS, Wang ES, Rizzieri DA, Vasu S, Rosenblat TL, Brooks CL, Habboubi N, Mughal TI, Kantarjian H, Konopleva M, Lane AA. Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. J Clin Oncol. 2022 Sep 10;40(26):3032-3036. Epub 2022 Jul 12. link to original article link to PMC article PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Blastic_plasmacytoid_dendritic_cell_neoplasm&oldid=89683"